GENFIT Secures €26.5 Million Milestone with Ipsen’s Iqirvo® Approval in Italy

Genfit SA ( (GNFT) ) has shared an update.

On May 20, 2025, GENFIT announced it will receive a €26.5 million milestone payment following the approval of pricing and reimbursement for Ipsen’s Iqirvo® in Italy, a treatment for Primary Biliary Cholangitis (PBC). This milestone under their Licensing and Collaboration Agreement with Ipsen marks a significant step for GENFIT, enabling further development of its pipeline in Acute On-Chronic Liver Failure (ACLF) and other critical diseases, thereby strengthening its position in the biopharmaceutical industry.

The most recent analyst rating on (GNFT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.

Spark’s Take on GNFT Stock

According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.

Genfit SA’s overall stock score of 59 reflects a blend of significant financial recovery and positive technical momentum, indicating a promising direction for the company. However, the high P/E ratio suggests that the stock may be overvalued, which is a key risk factor. While the financial performance shows improvement, the need for better operational efficiency and more balanced capital structure remain areas for improvement to support long-term growth.

To see Spark’s full report on GNFT stock, click here.

More about Genfit SA

GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. With a strong foundation in liver disease research, GENFIT has a diverse and expanding R&D portfolio, emphasizing Acute-on-Chronic Liver Failure (ACLF) and other serious conditions. The company is headquartered in Lille, France, and operates globally, with listings on both Nasdaq and Euronext.

Average Trading Volume: 13,785

Technical Sentiment Signal: Buy

Current Market Cap: $206.9M

For an in-depth examination of GNFT stock, go to TipRanks’ Stock Analysis page.